Ritlecitinib: Efficacy Of A Novel Therapy For Severe Alopecia Areata In Patients Aged 12 Years And Older

The study on ritlecitinib, a JAK3/TEC kinase inhibitor, demonstrates its efficacy in treating severe alopecia areata (AA) in patients aged 12 and older. In the ALLEGRO trial with 718 participants, 23% of those in the 50 mg group achieved significant hair regrowth by week 24. The treatment was effective across age groups, with better outcomes in patients without alopecia totalis or universalis. Long-term results showed sustained responses in 45.5% of patients, with 46% achieving complete regrowth. Ritlecitinib was well-tolerated, with no significant impact from demographic factors on its pharmacokinetics. Another study with 1,294 patients confirmed its safety, with mild side effects like nasopharyngitis and headaches. The findings suggest ritlecitinib as a promising option for severe AA, especially for extensive hair loss.